Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Capital Expenditures (2016 - 2025)

Lexaria Bioscience's Capital Expenditures history spans 9 years, with the latest figure at $1.0 for Q3 2025.

  • For Q3 2025, Capital Expenditures fell 100.0% year-over-year to $1.0; the TTM value through Nov 2025 reached $1.0, down 100.0%, while the annual FY2025 figure was $24646.0, 42.7% down from the prior year.
  • Capital Expenditures for Q3 2025 was $1.0 at Lexaria Bioscience, up from -$1.0 in the prior quarter.
  • Across five years, Capital Expenditures topped out at $43014.0 in Q3 2024 and bottomed at -$273375.0 in Q1 2021.
  • The 5-year median for Capital Expenditures is $6813.0 (2022), against an average of -$11161.4.
  • The largest annual shift saw Capital Expenditures tumbled 51.62% in 2022 before it plummeted 100.0% in 2025.
  • A 5-year view of Capital Expenditures shows it stood at $42375.0 in 2021, then crashed by 51.62% to $20500.0 in 2022, then plummeted by 35.38% to $13248.0 in 2023, then surged by 86.03% to $24645.0 in 2024, then tumbled by 100.0% to $1.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Capital Expenditures are $1.0 (Q3 2025), -$1.0 (Q2 2025), and $1.0 (Q1 2025).